Active, not recruitingPhase 1NCT02868567
Use of Dalfampridine in Primary Lateral Sclerosis
Studying Primary lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital for Special Surgery, New York
- Principal Investigator
- Dale Lange, MDHSS
- Intervention
- dalfampridine(drug)
- Enrollment
- 35 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2016 – 2026
Study locations (3)
- University of Florida Gainsville, Gainesville, Florida, United States
- Mass General Hospital, Boston, Massachusetts, United States
- Shara Holzberg, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02868567 on ClinicalTrials.govOther trials for Primary lateral sclerosis
Additional recruiting or active studies for the same condition.